These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26497577)

  • 1. SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML.
    Ma S; Yang LL; Niu T; Cheng C; Zhong L; Zheng MW; Xiong Y; Li LL; Xiang R; Chen LJ; Zhou Q; Wei YQ; Yang SY
    Sci Rep; 2015 Oct; 5():15646. PubMed ID: 26497577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 3. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
    Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
    J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
    Li X; Wang A; Yu K; Qi Z; Chen C; Wang W; Hu C; Wu H; Wu J; Zhao Z; Liu J; Zou F; Wang L; Wang B; Wang W; Zhang S; Liu J; Liu Q
    J Med Chem; 2015 Dec; 58(24):9625-38. PubMed ID: 26630553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
    Lin WH; Hsu JT; Hsieh SY; Chen CT; Song JS; Yen SC; Hsu T; Lu CT; Chen CH; Chou LH; Yang YN; Chiu CH; Chen CP; Tseng YJ; Yen KJ; Yeh CF; Chao YS; Yeh TK; Jiaang WT
    Bioorg Med Chem; 2013 Jun; 21(11):2856-67. PubMed ID: 23618709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N'-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo.
    Xu Y; Wang NY; Song XJ; Lei Q; Ye TH; You XY; Zuo WQ; Xia Y; Zhang LD; Yu LT
    Bioorg Med Chem; 2015 Aug; 23(15):4333-4343. PubMed ID: 26142317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia.
    Kim H; Lee C; Yang JS; Choi S; Park CH; Kang JS; Oh SJ; Yun J; Kim MH; Han G
    Eur J Med Chem; 2016 Sep; 120():74-85. PubMed ID: 27187860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.
    Yuan X; Chen Y; Zhang W; He J; Lei L; Tang M; Liu J; Li M; Dou C; Yang T; Yang L; Yang S; Wei Y; Peng A; Niu T; Xiang M; Ye H; Chen L
    J Med Chem; 2019 Apr; 62(8):4158-4173. PubMed ID: 30939008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
    Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
    Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.
    Hou P; Wu C; Wang Y; Qi R; Bhavanasi D; Zuo Z; Dos Santos C; Chen S; Chen Y; Zheng H; Wang H; Perl A; Guo D; Huang J
    Cancer Res; 2017 Aug; 77(16):4402-4413. PubMed ID: 28625976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
    Chen CT; Hsu JT; Lin WH; Lu CT; Yen SC; Hsu T; Huang YL; Song JS; Chen CH; Chou LH; Yen KJ; Chen CP; Kuo PC; Huang CL; Liu HE; Chao YS; Yeh TK; Jiaang WT
    Eur J Med Chem; 2015 Jul; 100():151-61. PubMed ID: 26081023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of quizartinib in the treatment of acute myeloid leukemia.
    Ostronoff F; Estey E
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
    Zarrinkar PP; Gunawardane RN; Cramer MD; Gardner MF; Brigham D; Belli B; Karaman MW; Pratz KW; Pallares G; Chao Q; Sprankle KG; Patel HK; Levis M; Armstrong RC; James J; Bhagwat SS
    Blood; 2009 Oct; 114(14):2984-92. PubMed ID: 19654408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.
    Diab S; Abdelaziz AM; Li P; Teo T; Basnet SKC; Noll B; Rahaman MH; Lu J; Hou J; Yu M; Le BT; Albrecht H; Milne RW; Wang S
    Eur J Med Chem; 2017 Oct; 139():762-772. PubMed ID: 28863357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML.
    Wang A; Li X; Chen C; Wu H; Qi Z; Hu C; Yu K; Wu J; Liu J; Liu X; Hu Z; Wang W; Wang W; Wang W; Wang L; Wang B; Liu Q; Li L; Ge J; Ren T; Zhang S; Xia R; Liu J; Liu Q
    J Med Chem; 2017 Oct; 60(20):8407-8424. PubMed ID: 28956923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
    Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
    Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
    Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.
    Heidary DK; Huang G; Boucher D; Ma J; Forster C; Grey R; Xu J; Arnost M; Choquette D; Chen G; Zhou JH; Yao YM; Ball ED; Namchuk M; Davies RJ; Henkel G
    J Med Chem; 2012 Jan; 55(2):725-34. PubMed ID: 22221201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.